Biomarker-guided Clinical Development of Multi-Peptide Cancer Vaccines: From discovery to phase III

In Prophylactic Vaccines, Therapeutic Vaccines by Freya SmaleLeave a Comment

download, cancer vaccine

IMA Product Concept:

  • Molecularly defined therapeutic cancer vaccines based on HLA-restricted peptides (short synthetic protein fragments binding to HLA receptors)
  • Unique platform (XPRESIDENTâ„¢) for identification of relevant tumor antigens confirmed to be naturally presented on real tumor tissue
  • Multiple peptides against multiple tumor targets
  • Fully synthetic off-the-shelf products, easily scalable, simple and low cost manufacturing process
  • Excellent tolerability (comparable to prophylactic vaccines)
  • Technology applicable to almost any tumor indication

Download the full presentation to find out all you need to know about Biomarker-guided Clinical Development of Multi-Peptide Cancer Vaccines: From discovery to phase III.

Biomarker-guided clinical development of cancer vaccines

  • Implementation of biomarkers as key guidance tool from discovery to phase III clinical trials
  • Use of cellular biomarkers (immunomonitoring)  to guide clinical design and predictive biomarkers to enrich clinical responders
  • Addressing key challenges early with regulatory agencies in Europe and US

Dr Toni Weinschenk, Director and Head of Discovery & Co-Founder, Immatics Biotechnologies

Download the full presentation here >

For more information about this and other topics discussed at the World Vaccine Congress Lyon, subscribe to the Vaccine Nation newsletter, or visit the event website.

For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Comment

Current ye@r *